Soleno Therapeutics - FDA Approval for Vykat XR Represents Significant Milestone!
Reading Time: 1 minute
Business drivers: Soleno Therapeutics (SLNO) specializes in the development of new therapies and medications for rare diseases. With the FDA approval for Vykat XR for the treatment of hyperphagia in Prader-Willi Syndrome (PWS) for patients aged 4 and older in March 2025, Soleno Therapeutics has achieved a significant breakthrough, with analysts estimating the drug's annual peak revenue potential to be as high as $2 billion. On July 10, Baird reaffirmed its Outperform rating and raised the price target from $105 to $120.
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
